Epidemiology of HIV and Access to Prevention services, Tanzania Joint Biennial HIV National Response Review Stakeholders meeting. November, 2014 Blue Pearl.

Slides:

Advertisements

Similar presentations

Women and ARV-based Prevention: Challenges and Opportunities Tim Mastro, MD, DTM&H AIDS 2014 Melbourne, Australia 24 July 2014.

Advertisements

STDs Valerie Robinson D.O.. Prevention Abstinence Risk reduction Vaccines Male or female condoms Cervical diaphragm might protect against cervical GC,

Dr. Carol Odula (Obs./Gyn.) May 7 th 2013 Preparing for pre-exposure prophylaxis (PrEP) to prevent HIV infection.

Modelling the expected distribution of new HIV infections by exposure group.

From “What If” to “What Now” Perspectives on ARVs and the Future of Treatment and Prevention Mitchell Warren Executive Director, AVAC IAS 2011, Rome.

HIV Prevention Programs Among Older Adult Populations

PREVENTION OF HIV-1 Myron S. Cohen, MD Institute for Global Health The University of North Carolina.

Maurice Cook ( EM Designs Group, Inc.) The End of AIDS Transmission? Robert M Grant, June 2012.

Preparing for pre-exposure prophylaxis (PrEP) to prevent HIV infection James Wilton Project Coordinator Biomedical Science of HIV Prevention

HIV in Texas: The Ways Forward Ann Robbins Manager of HIV/STD Prevention and Care Department of State Health Services.

Does Africa need a rectal microbicide? IRMA and AVAC presentation 27 September 2011 Salim S. Abdool Karim Pro Vice-Chancellor (Research), University of.

HIV Prevention Biomedical A New Landmark in the Field of HIV Treatment

Combination Prevention of HIV: What is it and where are we now?

INA-RESPOND Test and Treat Study

THE EPIDEMIOLOGY OF HIV/AIDS. HIV/AIDS – USA 2009 Living with HIV/AIDS = 1.2 million Incidence = 56,000/year MSM = 53% Heterosexuals = 31% IDUs.

Accelerating Anti-Retroviral Treatment as a catalytic action for Ending AIDS Pride Chigwedere, MD, PhD Senior Advisor to the African Union AWA CONSULTATIVE.

How well are we doing in preventing HIV and how can we do better?

P REPARING FOR P RE P: FROM THEORY TO PRACTICE K EY POPULATIONS Dr Oscar Radebe.

HIV Science Update: From Rome to Addis – Biomedical Prevention Elly T Katabira, FRCP Department of Medicine Makerere University College of Health Sciences.

Are people living with HIV less likely to pass HIV to others if they are on treatment? Exploring the use of treatment as prevention James Wilton Project.

Use of Antivirals in Prevention Oral and Topical Prophylaxis

The potential and challenges of ARV-based HIV prevention: An overview

Monitoring the effects of ARV treatment programmes on prevention Gabriel Mwaluko 1, Mark Urassa,2, John Changalucha,2, Ties Boerma 3 1 TANESA Project,

Washington D.C., USA, July 2012www.aids2012.org Implementation Science: Realizing the HIV Prevention Revolution Nelly R. Mugo, MD, MBChB, MMed, Kenyatta.

Introduction to HIV New Prevention Technologies (NPTs)

Topical, Oral; Daily, Intermittent; Single, Combination agents; What do we need AND what will work? Patrick Ndase, Microbicide Trials Network & Dep’t of.

Slide 1 of 9 From J Marrazzo, MD, at Los Angeles, CA: April 22, 2013, IAS-USA. IAS–USA Jeanne Marrazzo, MD, MPH Professor of Medicine University of Washington.

Summarising Male Circumcision Efficacy: Results of the three randomised clinical trials Neil A Martinson Perinatal HIV Research Unit.

Cindra Feuer and Marc-André LeBlanc HRCF, 21 April 2010 ARV-based Prevention.

October 8, 2010 USAID Mini-University Clancy Broxton, MA, MPH Most At Risk Populations Advisor USAID Office of HIV/AIDS HIV Prevention for Most At- Risk.

State of the Art: Epidemiology and Access

Microbicide research in Africa: Partnership in Action Salim S. Abdool Karim, MD, PhD Director: CAPRISA Pro Vice-Chancellor (Research): University of KwaZulu-Natal.

HIV/AIDS BI-ANNUAL REVIEW 2008 Prevention -Goal, Indicators and Targets TACAIDS.

Biomedical Approaches to HIV Prevention HIV Research Catalyst Forum April 21, 2010, Baltimore, MD Monica S. Ruiz, PhD, MPH George Washington University.

Myron S. Cohen, MD Associate Vice Chancellor Director, Institute for Global Health The University of North Carolina.

Washington D.C., USA, July 2012www.aids2012.org Summary of Track C: Epidemiology and Prevention Science Audrey Pettifor, UNC Christopher Hurt, UNC.

Looking back, looking forward: what we know and don’t know about oral PrEP and tenofovir gel for preventing HIV in women Jared Baeten MD PhD Departments.

Looking back, looking forward: what we know and don’t know about oral PrEP and tenofovir gel for preventing HIV in women Jared Baeten MD PhD Departments.

TRACK C RAPPORTEURS REPORT. Prepared by Anne BuvéBelgium Anne BuvéBelgium Sabina Bindra-BarnesIndia Sabina Bindra-BarnesIndia Saidi KapigaTanzania Saidi.

A PEP and PrEP Update Jeffrey D. Klausner, MD, MPH Black AIDS Institute-UCLA African-American University September 2014 Special thanks to Raphael Landovitz,

National Working Group on Microbicides The Basics of Microbicides Amitrajit Saha PATH January 2007.

Ethics in a new era Microbicides 2012 Preconference Bridget Haire.

Global overview of the state of the epidemic and new strategies of Response Peter Godfrey-Faussett, Senior Science Adviser, UNAIDS Karl Dehne, Chief, Prevention,

An update on PrEP, PEP and Treatment as Prevention Francois Venter Wits Reproductive Health & HIV Research Institute (RHI) AWAAC 2015.

IAS July 1 The Caprisa 004 result in context Sheena McCormack Clinical Scientist MRC Clinical Trials Unit.

Jeanne M. Marrazzo, MD, MPH Professor of Medicine University of Washington Seattle, Washington A Shot in the Arm for HIV Prevention? Opportunities and.

THE 6 TH NATIONAL SCIENTIFIC CONFERENCE ON HIV/AIDS Ending the AIDS epidemic: Science, Policy and Community Peter Godfrey-Faussett UNAIDS, Geneva.

HIV STIGMA: FROM GLOBAL TO LOCAL Brandon Brown, PhD UCR SOM Department of Social Medicine and Population Health.

PrEP Update: The science, new tools, and next steps Dawn K. Smith MD, MS, MPH Division of HIV/AIDS Prevention, CDC “The findings and conclusions in this.

N ORTHWEST A IDS E DUCATION AND T RAINING C ENTER Pre-exposure Prophylaxis for HIV Prevention Efficacy and the importance of adherence Joanne Stekler,

Effective HIV & SRH Responses among Key Populations Module 2: The Comprehensive Package of Programmes and Services.

Advances in Biomedical HIV Prevention Interventions

New Prevention Technologies Workshop Module 2: NPTs in context

Antiretrovirals for HIV Prevention: Progress and Challenges Kenneth H. Mayer, M.D. Brown/Miriam/Fenway.

The Uganda Country Presentation EAC Think Tank on HIV Prevention 24th to 26 th February 2009 Laico Regency Hotel, Nairobi, Kenya Republic of UgandaUganda.

HIV and Women Collaborating Across Borders to Advance the Health of Women IAS 2012 Gina M. Brown, M.D. July 22, 2012.

Prevention Science Gaps and the HIV/AIDS Pandemic Quarraisha Abdool Karim, PhD Head: CAPRISA Women and AIDS Pogramme Associate Professor in Epidemiology,

Track C: Epidemiology, prevention and prevention research Quarraisha Abdool Karim (Chief Rapporteur) Team: Marian Swart, Ken Mayer, Cheryl Baxter, Ayesha.

Pre-exposure Prophylaxis (PrEP) for HIV Prevention: What’s the Future? Joanne Stekler, MD MPH Assistant Professor of Medicine University of Washington.

Session: Treatment is Prevention? 16 th International Conference on AIDS and Sexually Transmitted Infections in Africa, Addis Ababa, Ethiopia Catherine.

Prepping Men who have Sex with Men for better Health Outcomes: A Conversation between Healthcare Providers and their Clients Tuesday 25th July at 11:00.

PrEP: A Case-by-Case Approach

Managing Women Living With HIV Infection

PrEP Effectiveness. Preexposure Prophylaxis Translating the Clinical Trials Into Clinical Practice.

Module 1: INTRODUCTION TO ORAL PrEP Version: August 2018.

Module 1: INTRODUCTION TO ORAL PrEP Version: December 2018.

Module 1: INTRODUCTION TO ORAL PrEP Version: August 2018.

The Burden of HIV/AIDS in Africa: New Hope, New Challenges

Module 1: INTRODUCTION TO ORAL PrEP Version: June 2019.

Presentation transcript:

Epidemiology of HIV and Access to Prevention services, Tanzania Joint Biennial HIV National Response Review Stakeholders meeting. November, 2014 Blue Pearl Hotel ( David Sando, Sam Sumba, Geoffrey Somi and Raphael Kalinga) JBSNR 11-13, Nov 14. Blue Pearl Hotel 1

Outline Trends and distribution of HIV incidence and prevalence Risk factors and access to Preventions service Recommendation for Joint annual review JBSNR 11-13, Nov 14. Blue Pearl Hotel 2

HIV incidence and MTCT rates JBSNR 11-13, Nov 14. Blue Pearl Hotel 3

4

5

6

7

8

9

10

Outline Trends and distribution of HIV incidence and prevalence Risk factors and access to Preventions service Recommendation for Joint annual review JBSNR 11-13, Nov 14. Blue Pearl Hotel 11

Effectiveness (%) Effect size (95%CI) MTN Daily microbicide for women15% (-21; 40) CAPRISA Coital microbicide for women 31% (1; 51) iPrEX - Daily PrEP for MSM 44% (15; 63) TDF2 - Daily PrEP for heterosexual men and women 62% (22; 84) HPTN ART for prevention 96% (73; 99) PartnersPrEP - Daily PrEP for discordant couples 73% (49; 85) FEM-PrEP - Daily oral PrEP for women 6% (-52; 41) Sexual transmission prevention Prevention in IDUs Bangkok Tenofovir Study - Daily oral PrEP for IDUs 49% (10; 72) RV144 - HIV vaccine 39% (6; 60) Mwanza - STD treatment 42% (21; 58) Medical male circumcision 54% (38; 66) Source: adapted from Abdool Karim SS. Lancet 2013 Clinical trial evidence for preventing sex/IDU HIV transmission-July 2013 JBSNR 11-13, Nov 14. Blue Pearl Hotel 12

Note: PMTCT, Screening transfusions, Harm reduction, Universal precautions, etc. have not been included – this is on sexual transmission Behavioural Intervention - Abstinence - Be Faithful HIV Counselling and Testing Coates T, Lancet 2000 Sweat M, Lancet 2011 Male Condoms Female Condoms Treatment of STIs Grosskurth H, Lancet 2000 Male circumcision Auvert B, PloS Med 2005 Gray R, Lancet 2007 Bailey R, Lancet 2007 Treatment for prevention Cohen M, NEJM, 2011 Donnell D, Lancet 2010 Tanser, Science 2013 Microbicides for women Abdool Karim Q, Science 2010 Grant R, NEJM 2010 (MSM) Baeten J, NEJM 2012 (Couples) Paxton L, NEJM 2012 (Heterosexuals) Choopanya K, Lancet 2013 (IDU) Oral pre-exposure prophylaxis Post Exposure prophylaxis (PEP) Scheckter M, 2002 ARV prophylaxis ARV prophylaxis HIV PREVENTION JBSNR 11-13, Nov 14. Blue Pearl Hotel 13

HIV Counseling and Testing JBSNR 11-13, Nov 14. Blue Pearl Hotel 14

Condom use and HIV JBSNR 11-13, Nov 14. Blue Pearl Hotel 15

VMMC status and targets JBSNR 11-13, Nov 14. Blue Pearl Hotel 16

JBSNR 11-13, Nov 14. Blue Pearl Hotel 17

JBSNR 11-13, Nov 14. Blue Pearl Hotel 18

JBSNR 11-13, Nov 14. Blue Pearl Hotel 19

JBSNR 11-13, Nov 14. Blue Pearl Hotel 20

Access to HEID services, 2013 JBSNR 11-13, Nov 14. Blue Pearl Hotel 21

Education attainment and HIV JBSNR 11-13, Nov 14. Blue Pearl Hotel 22

Age at sexual debut, JBSNR 11-13, Nov 14. Blue Pearl Hotel 23

Multiple sexual partners in Tanzania JBSNR 11-13, Nov 14. Blue Pearl Hotel 24

Outline Trends and distribution of HIV incidence and prevalence Risk factors and access to Preventions service Recommendation for Joint annual review JBSNR 11-13, Nov 14. Blue Pearl Hotel 25

New infections by mode of transmission JBSNR 11-13, Nov 14. Blue Pearl Hotel 26

JBSNR 11-13, Nov 14. Blue Pearl Hotel 27